SmartinBio raises $151,000 from Hanlim Pharmaceutical for TRAP1 drug work
What's the deal? SmartinBioDealroom has a profile for this one. Try Dealroom → has raised US$167.7K from Hanlim Pharmaceutical, which led the round. The Korean biotech develops treatments based on inhibiting TRAP1, a protein that regulates mitochondrial function.
What's the endgame? SmartinBio is using its TRAP1-inhibitor platform to build a treatment for diabetic retinopathy and a cancer therapy. The funding is meant to advance that technology and move it toward commercialisation.
Why now? The deal grew out of a research support programme run by the Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), which has backed SmartinBio's work since 2022. The foundation's preclinical centre connects startups with technology-commercialisation events and industry partners.
With the investment, SmartinBio plans to tap Hanlim's manufacturing and regulatory capabilities to expand its base for growth.
The signal: The round is small, but it shows how established pharmaceutical firms are using early-stage deals to secure access to novel drug platforms before they reach the clinic.
Read more: wowtale.net
Image credit: National Institutes of Health (NIH)
